PEARL: Postmenopausal evaluation and risk-reduction with lasofoxifene
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Bone resorption; Breast cancer; Cardiovascular disorders; Fracture; Postmenopausal osteoporosis
- Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms PEARL
- Sponsors Ligand Pharmaceuticals
- 11 Oct 2010 Cardiovascular outcomes published in Circulation.
- 25 Feb 2010 Results published in New England Journal of Medicine.
- 11 Dec 2008 Results were presented at the 31st Annual San Antonio Breast Cancer Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History